AstraZeneca (LSE:AZN) remains one of the most closely watched names on the London market, a pharmaceutical heavyweight straddling the UK, Sweden and, increasingly, the United States. After a first half of 2026 that combined solid growth with a clutch of pipeline disappointments, the debate has sharpened: can chief executive Pascal Soriot's research engine keep delivering the catalysts needed to justify the company's premium standing and its ambition of $80bn in Revenue by 2030?
Latest developments
In February 2026 AstraZeneca (LSE:AZN) began trading directly on the New York Stock Exchange, giving what it called “equal weight” to its UK, Swedish and US listings while keeping London as its primary listing — a move accompanying a reaffirmed pledge to invest $50bn in the United States by 2030 amid Tariff pressure, even as it paused a planned UK headquarters expansion.
Its half-year results in late July showed around 30 regulatory approvals since late 2025, including US clearance for the hypertension therapy baxdrostat and expanded uses for Enhertu and Fasenra, plus six positive Phase III readouts. The period also brought setbacks, with trials for Wainua, Imfinzi and Ultomiris missing primary endpoints, and a wave of China licensing deals.
Financial and operational picture
First-half total revenue rose 9% (6% at constant currencies) to $30.7bn, with product sales up 8% and alliance revenue up 31%. Core Earnings Per Share increased 12% to $5.21, while reported EPS reached $3.60. The Interim Dividend was lifted three cents to $1.06 a share, with the company signalling an intent to raise the annual dividend to $3.30.
Net Debt climbed to $26.9bn as Capital spending accelerated. For the full year, AstraZeneca guides to a mid-to-high single-digit revenue rise and low-double-digit core EPS growth at constant currencies.
What could drive the shares next?
Soriot has pointed to more than twenty high-value readouts over the following 18 months, and the cadence of those trial results is the principal swing factor. Progress toward the $80bn 2030 revenue ambition, momentum in oncology and in cardio-renal-metabolic launches, and delivery of the vast US Manufacturing build-out all feed the narrative. Resolution of US tariff and drug-pricing uncertainty would remove an overhang.
The clutch of China licensing deals struck during the year — spanning agreements with domestic partners such as CSPC and Dizal — underlines how central the region has become to AstraZeneca's growth ambitions, even as it adds a layer of geopolitical complexity. Meanwhile, the direct New York listing may, over time, broaden the Shareholder base and sharpen the debate over where the group's centre of gravity lies, a sensitivity for its London-focused investors.
Risks to watch
Pipeline attrition is the ever-present danger, as the recent Wainua, Imfinzi and Ultomiris misses show; late-stage failures can move the shares sharply. US pricing and tariff policy, rising net debt and heavier capital intensity, and expanding exposure to China's regulatory and geopolitical landscape all Warrant attention. Currency swings can also flatter or depress reported growth given the dollar-reporting base, and the sheer breadth of the late-stage pipeline means investors must track a long list of individual readouts, any of which can move the shares on a single day.
Investor takeaway
AstraZeneca's first half showed a Business still growing at a healthy clip while investing heavily for the next decade. The story from here rests on execution: converting a dense pipeline into approvals, funding the US expansion without straining the balance sheet, and navigating a tense policy backdrop. Investors will focus on the run of late-stage data readouts, updated commentary on the 2030 revenue target and any clarity on US tariffs as the clearest markers of whether the FTSE giant can stay on top.






Please wait processing your request...